Cochereau I, Diraison M C, Mousalatti H, Bouyer I, Ren L, Guvenisik N, Hoang-Xuan T
Service d'Ophtalmologie, Hôpital Bichat, Paris.
J Fr Ophtalmol. 2000 Feb;23(2):123-6.
To assess the efficacy and tolerability of high-dose (2000microg) intravitreous ganciclovir in the maintenance therapy of CMV retinitis in AIDS patients.
and methods: Prospective open study in a single center. The maintenance therapy of CMV retinitis consisted of a single high-dose (2000microg) intravitreous injection per week. The evaluation criteria were clinical examinations, and photographs when necessary.
Over a 44-week period, twenty-four eyes (15 patients) have been included. The relapse rate evaluated by the survival curves method was 5% at 44 weeks. No ocular toxicity was reported after a follow-up of 24 weeks.
High-dose intravitreous ganciclovir induces a prolonged remission of CMV retinitis and is well tolerated. Therefore, we recommend the use of the 2000microg dosage per intravitreous injection instead of the classical dosage of 400microg.
评估高剂量（2000微克）玻璃体内注射更昔洛韦在艾滋病患者巨细胞病毒性视网膜炎维持治疗中的疗效和耐受性。
在单一中心进行的前瞻性开放性研究。巨细胞病毒性视网膜炎的维持治疗包括每周一次高剂量（2000微克）玻璃体内注射。评估标准为临床检查，必要时进行拍照。
在44周期间，纳入了24只眼（15例患者）。通过生存曲线法评估的44周时复发率为5%。随访24周后未报告眼部毒性。
高剂量玻璃体内注射更昔洛韦可诱导巨细胞病毒性视网膜炎长期缓解，且耐受性良好。因此，我们建议每次玻璃体内注射使用2000微克剂量而非传统的400微克剂量。
